Women in their mid-teens through their 30s, just prior to perimenopause, typically produce an average of 250 pg/ml, but potentially up to 800 pg/ml, of estradiol on day 12 of their menstrual cycle. These levels, though seemingly high, are physiologically necessary for establishing progesterone receptors for the luteal phase of the cycle.
Many practitioners typically target estradiol levels of approximately 70 ng/ml when using low-dose hormone replacement therapy (HRT) to address menopausal symptoms. However, such levels may only be sufficient to alleviate symptoms and may not provide the necessary gene signaling for optimal health. Additionally, administering estrogen and progesterone, even in the form of bioidentical compounds, in static low-dose regimens is not physiologically reflective of the natural hormonal patterns in healthy, fertile women.
The hormone levels in Physiologic Hormone Replacement Therapy (HRT) are not high; they are designed to mimic the same levels that women naturally produce during their reproductive years.